Watanabe A, Nakai Y, Saito J, Motomiya M
Department of Internal Medicine, Tohoku University, Sendai, Japan.
Gan To Kagaku Ryoho. 1992 Feb;19(2):184-8.
We have analyzed the clinical significance of secondary infections associated with lung cancer patients. The incidence of secondary infections was 51.4% in 214 in-patients with lung cancer admitted to our institution in 1988 and 1989, and almost all of them had respiratory tract infections. The incidence was high in patients with cell types other than adenocarcinoma, and in those with hypoproteinemia, impaired cellular immunity and obstruction of the airway. The prognosis in patients with infection was much poorer than that in patients without infection. Major causative pathogens were Staphylococcus aureus including methicillin-resistant S. aureus (MRSA), Haemophilus influenzae, Klebsiella spp. and Pseudomonas aeruginosa. These pathogens except for H. influenzae were isolated at the terminal stage, in cases with airway obstruction and in post cancer-chemotherapeutic phase. The efficacy rate of 194 chemotherapeutic regimens against infection was 57.7%. Although the efficacy rate in 1988 and 1989 exceeded that in the 1970s, there was no significant difference in the efficacy rate between monotherapy (57.1%) and combined therapy (59.3%). The effectiveness was very poor for infections caused by P. aeruginosa and MRSA, or for cases with airway obstruction and marked impairment of pulmonary blood flow. The above results showed that a new combined therapy as well as the measures to improve the general condition of compromised hosts are required in the treatment of secondary infections in these patients.
我们分析了肺癌患者继发感染的临床意义。1988年和1989年我院收治的214例肺癌住院患者中,继发感染的发生率为51.4%,且几乎所有患者均为呼吸道感染。腺癌以外细胞类型的患者、低蛋白血症患者、细胞免疫功能受损患者及气道阻塞患者的感染发生率较高。感染患者的预后比未感染患者差得多。主要致病菌为金黄色葡萄球菌,包括耐甲氧西林金黄色葡萄球菌(MRSA)、流感嗜血杆菌、克雷伯菌属和铜绿假单胞菌。除流感嗜血杆菌外,这些病原菌在疾病终末期、气道阻塞病例及癌症化疗后阶段被分离出来。194种抗感染化疗方案的有效率为57.7%。尽管1988年和1989年的有效率超过了20世纪70年代,但单药治疗(57.1%)和联合治疗(59.3%)的有效率之间没有显著差异。对于由铜绿假单胞菌和MRSA引起的感染,或气道阻塞及肺血流明显受损的病例,疗效非常差。上述结果表明,在治疗这些患者的继发感染时,需要一种新的联合治疗方法以及改善免疫功能低下宿主一般状况的措施。